Merck KGaA (MRK) Earnings Call Transcript & Summary
November 12, 2026
Earnings Call Speaker Segments
Florian Schraeder
executiveThanks so much, Maddalena. Good afternoon and good morning to all of you, and welcome to the call covering our Q3 2026 results. We appreciate you being with us today. I’m Florian Schraeder, Head of Investor Relations at Merck; on this call, Kai Beckmann, our Group CEO, will begin with an update on the actions we took during the summer that relate to the new strategic direction. After that, in his executive summary, he’ll focus on how the business performed in the third quarter and on the key developments. Helene von Roeder, Group CFO, will walk through the financial overview in greater detail. Before we move to your questions, Kai will provide our revised outlook and guidance. Jean-Charles Wirth, CEO of Life Science, Danny Bar-Zohar, CEO of Healthcare, and Benjamin Hein, CEO of Electronics, will be with us for the Q&A. It’s a pleasure to hand things over to Kai to get us started.
Kai Beckmann
executiveRight, thanks Florian, and good afternoon — or good morning, depending on where you're joining from — and thanks to all of you for being here today; let's go ahead and begin. To start, I'd like to give you an update on the strategic direction we laid out in May and are detailing for you today. As you're aware, that direction has four streams: concentrating on high-growth value drivers, moving selected product portfolios toward integrated workflows, connecting and leveraging platform capabilities throughout our business, and scaling and sourcing innovation through M&A and in-licensing. We've gone further in defining how we approach high-growth value drivers — which we describe as sizable, rapidly expanding end market segments where we aim to keep reinforcing our position. We've pinpointed four segments: biomanufacturing, discovery, and development along the life sciences value chain, semiconductor manufacturing supporting AI and advanced nodes, and targeted specialty and rare diseases. On the rare disease front, I'm sure you saw Tuesday's positive news. The FDA approved PIMJETMI — the brand name for pimicotinib — as a systemic treatment for patients who have symptomatic tenosynovial giant cell tumors. That marks a significant milestone as we work to broaden the reach of our rare diseases franchise. Growth for us isn't only about M&A investment; it also hinges on how well we execute. Looking at our strategic direction next to the results of recent quarters, the pieces come together; with that, let's go to the next slide and talk through the quarter's highlights. It's fair to say the third quarter produced solid results, and over the past few months we've kept advancing our strategic priorities throughout the business. As you know, earlier this year we laid out where the strongest growth opportunities lie. During this quarter we took additional steps in that direction and worked to better serve the needs of patients and customers. Before turning to the numbers, I want to highlight several developments that demonstrate how our strategic direction is being put into action. Taken together, they reflect three themes: strengthening capabilities, sharpening the portfolio, and investing in our global footprint. In October we announced the planned acquisition of Silence Therapeutics — a strategically important step toward bolstering our mid-stage pipeline that, if completed, would bring in divesiran, a phase III-ready siRNA candidate for treating polycythemia vera. The acquisition fits our focus on targeted specialty and rare diseases. We also view it as a chance to expand into hematology down the road. The transaction should close in the first quarter of 2027, subject to customary closing conditions. At the same time, our strategic agenda is also about making choices and sharpening the portfolio. That's why last week we announced the planned divestment of our CDMO business to Lonza. This marks one more significant move forward on our mid- to long-term strategic agenda, letting us lower capital intensity and sharpen the portfolio’s focus on businesses that create strong value. We expect the deal to close around mid-2027, assuming regulators give their approvals and the usual closing conditions are met. I’m also glad to report that only a handful of steps remain before we complete the Bio-Techne acquisition. That milestone matters a great deal, since it could deliver world-class R&D and innovation to underpin growth in Life Science Discovery and Development. During our June 25th investor call, we said we anticipated that adding Bio-Techne ought to be immediately accretive to sales growth and margins, and we still expect a contribution this year, though the transaction’s actual closing date hasn’t been fixed. I’ll go through the specifics when we update guidance in a few minutes. Alongside these portfolio decisions, we’re putting money into our worldwide footprint through site openings in Daejeon, Sheboygan, and Darmstadt; our new Asia-Pacific bioprocessing center in Daejeon, South Korea, is now formally open. Backed by more than EUR 300 million of investment, this site reinforces our in-region, for-region pledge across Asia-Pacific and around the world. It also bolsters South Korea’s expanding position as a regional hub for biopharmaceutical manufacturing; in Sheboygan, Wisconsin, we cut the ribbon on a new 38,000 sq ft research and development facility centered on materials for next-generation chip manufacturing, which forms part of our $200 million multi-year commitment to U.S. Semiconductor Solutions capabilities; in Darmstadt, we introduced a new EUR 25 million BioReliance testing facility in July. That site adds capacity within the European Union for commercial drug substance and drug product release testing. It puts these services nearer to biopharmaceutical customers throughout the region. With that, I’ll move to a summary of how we performed financially in the third quarter. After a robust first half of 2026, our growth momentum carried through the third quarter. Organic sales growth picked up to 5.1%, helped meaningfully by Life Science and Electronics. Healthcare sales likewise rose sequentially in spite of persistent headwinds. Life Science gained across every region. Process Solutions once more turned in a strong showing, posting organic sales growth of 10.5%. Advanced Solutions kept up solid growth, and Discovery Solutions posted modest growth, aided by markets that are stabilizing. Within Healthcare, every franchise but Specialty Care helped keep sales broadly stable. The Rare Diseases portfolio contributed to organic growth for the first time, growing in the mid-double-digit percentage range. Cardiometabolic, together with Fertility and Endocrinology, each posted mid-single-digit growth. Specialty Care headwinds grew sharper as Mavenclad’s loss of exclusivity in the U.S. sped up sales erosion in Q3.. In Electronics, organic growth accelerated noticeably, hitting 13% in the third quarter. Semiconductor Solutions expanded strongly, with organic sales up 19%, carried by ongoing momentum at advanced nodes. Optronics was broadly flat, and headwinds in consumer electronics and markets are expected to build further. All told, we met our goal of profitable organic growth for the Group while we keep investing in innovation. When you compare EBITDA pre-growth year over year, Q3 2025 carried material one-off effects that weighed on that comparison. Helene is going to walk through more of that in a moment. Strong cash generation stood out as another highlight, and it pushed our leverage ratio even lower ahead of the anticipated close of the Bio-Techne acquisition. Given how strong these results were, we lifted our full-year guidance yet again. I'll come to the specifics on that later in this call. Now let's dig into the growth composition for sales and EBITDA pre, starting on page seven; during this quarter, organic growth, foreign exchange rates, and portfolio changes combined in a way that was more favorable than in H1, which helped growth momentum accelerate. Reported net sales growth year over year came in at 5.8% for Q3, which is 240 basis points above the 3.4% reported growth rate in Q2. Organic sales growth landed 100 basis points higher, at a rate of 5.1%, following 4.1% in Q2. Foreign exchange effects turned from negative during the first half to positive in Q3, adding 1.5 percentage points. Portfolio effects contributed a slightly negative impact of 0.8 percentage points. Organic EBITDA pre-growth of 0.4% held up well even though one-off support was lower by a net double-digit million amount versus Q3 2025. I'll now pass things to Helene, who has further details to share.
Helene von Roeder
executiveThanks a lot, Kai, and a very warm welcome from me as well. Let's dig into the specifics of how we performed financially in the third quarter. I'll begin with reported growth and the key metrics you'll find on slide nine. As Kai already mentioned, the mix moved quite a bit versus Q2 and was, on balance, strongly in our favor. You all know that reported leveraged growth and robust cash generation, whether that growth comes organically or through external means, are going to matter more and more in the year ahead. With that in mind, let me say a few words about Bio-Techne and the planned divestment of the CDMO business. For 2027, we anticipate Bio-Techne contributing a portfolio effect of nearly 5% to Group reported sales growth and roughly 10% to Life Science reported sales growth. Once the closing happens, which we anticipate next year, we will put a more precise number on the CDMO-related effect. We expect both Bio-Techne and the CDMO sale to be immediately accretive to group and Life Science EBITDA pre-margins once closing occurs. Back to Q3: EBITDA pre rose 0.8%. The Q3 2025 comparison had the benefit of a 60 million gain from selling a priority review voucher plus another EUR 59 million tailwind stemming from legislative changes in South America. EPS pre came in flat versus the prior year in Q3. A smaller negative financial result was offset by greater depreciation and amortization. Reported EPS took a hit from an impairment tied to the CDMO business sale, and that same item pushed our calculated tax rate up to 23.9% in Q3, which leaves us at 23.2% year to date. One housekeeping note: starting in 2027, we anticipate our underlying tax rate landing in the 22%-24% range, a full percentage point above the range we've seen in prior years. The main reason is the shifting geographic mix of our profits. Weaker demand for certain healthcare products made in Switzerland is steadily lowering Switzerland's share of group profit, which raises the weight of profits booked in higher tax jurisdictions. Now let's move to financial performance by business sector, beginning with Life Science on slide 10. Organic sales were up 6.1% year-over-year. If you strip out the tariff refunds to customers, that growth figure becomes 7.3%. Once again Process Solutions drove the growth, rising 10.5%, and that includes tariff-related headwinds. The underlying growth rate was 12.6%, powered by customer projects and downstream. In contrast to the first half of 2026, no extraordinary effects lifted growth this time. Underlying demand and customer capacity expansion stayed strong, though you may remember that in August we discussed order book trends that signaled a softer fourth quarter. Even with a challenging environment, Discovery Solutions posted organic sales growth of 1.7%, or 22.4% once customer refunds are excluded. On the whole, academia was stabilizing, though regional patterns still differed sharply. We also saw more strength in business with customers in the industry and testing segment. Advanced Solutions kept delivering solid results, with organic growth of 4.3%. The key growth engines in this period were CDMO, biomonitoring, and lab water. Every region outside China expanded, with the Americas and the rest of Asia Pacific leading the way. China sales came in just a bit under the previous year. To get ahead of a question you might already have, the CDMO assets that we agreed to divest to Lonza represented under 10% of Q3 sales in Advanced Solutions. The EBITDA pre-margin tied to those assets sat below the Life Science sector's margin. That gives you context for what I said earlier regarding the margin accretion we expect once the closing occurs; and let me also wrap up the tariffs discussion at this point. As Q3 is now complete, we have recognized every tariff-related effect. The total top line impact year-to-date came to EUR 35 million, with EUR 26 million of that recognized in Q3. For Life Science, EBITDA pre increased 8.7%, driven primarily by higher volumes and Process Solutions, with an added boost from tariff refunds we received. Those gains were partly offset by greater R&D spending and capacity expansion. Moving to Healthcare, which brings us to slide 11, improvements in rare disease, cardiometabolic, and fertility and endocrinology were countered by a drop in specialty care. Our rare disease portfolio continued to advance. Q3 was the first quarter in which it added to organic growth. OGSIVEO and Gomekli delivered robust year-over-year increases of 25% and 80%, respectively; in Q4, the typical year-end stocking patterns could appear. Even so, we'll continue working to speed up the underlying uptake in the U.S. Looking ahead to other regions as well. Fertility and endocrinology returned to organic growth. The U.S. price effect for Gonal-f from the prior year has mostly annualized, and Pergoveris and Saizen each posted double-digit percentage growth. Mavenclad again achieved double-digit growth in Europe, though erosion in the U.S. accelerated in Q3. Our revised 2026 guidance still reflects only what has been booked for U.S. sales so far. Erbitux growth once more offset the decline in specialty care, supported by the BREAKWATER regimen. EBITDA pre benefited from strong cost discipline and sequentially stable R&D expense, which offset margin pressure tied to lower Mavenclad sales. Since we anticipate Mavenclad's U.S. sales will keep eroding, and with launch preparations plus expansion of phase III projects, we expect the EBITDA pre margin to decline from here. Still, reaching a margin above 30% stays our top priority going forward as well; that's also true considering possible effects tied to a phase III start for divesiran, after the anticipated closing of the Silence Therapeutics acquisition in Q1 of next year. Turning now to Electronics. The Electronics business sector sped up its growth once more in Q3. We saw organic growth of 13%, and it was spread broadly across every key region. Momentum was strong as advanced nodes ramped up in both logic and memory, helped along by AI demand. Every part of the Semiconductor Solutions portfolio pitched in, driving very strong organic growth of 19%. Beyond solid volume gains and a favorable mix, sales received a lift from price adjustments made in response to higher raw material costs. We view that additional contribution as temporary and expect it to taper off as market conditions return to normal during 2027. Optronics came in roughly flat. Even so, let me repeat what I noted in August. The business keeps encountering headwinds from weaker demand for consumer electronics, which high memory prices are affecting. We still assume this may lead to a steeper year-over-year drop in net sales for Q4. In summary, we delivered a strong underlying performance in the Electronics business during Q3, including meaningful operating leverage; it was a clean quarter with no material one-off effects. EBITDA pre rose organically by over 17% to EUR 279 million. The Q3 margin of 29.5% shows additional progress in our operating performance. Going forward, we still see room for further gradual enhancement of our underlying EBITDA margin, backed by volumes, mix, and cost discipline. A few remarks on a key development in our balance sheet, which mirrors the impact of the portfolio measures we intend to carry out in the months ahead.
Helene von Roeder
executiveBy the end of September, total assets came in at EUR 53.7 billion, compared with EUR 51.5 billion last December and EUR 52.7 billion in June. Cash and cash equivalents went up as we prepare for the payment related to the Bio-Techne acquisition. Strong underlying free cash flow and the liquidation of short-term investments were the primary factors behind that. The year-to-date rise in receivables and inventories mirrors how the business is expanding. Receivables, though, held steady on a sequential basis even with additional growth, which reflects better cash collection processes. Inventories came down quarter-on-quarter even as Life Science and Electronics continued to grow strongly. The gain in other assets stemmed from recognizing CDMO assets held for sale, Bio-Techne hedging measures, and equity investments. Turning to equity and liabilities, our equity ratio climbed to 59% from 57% in Q2, helped by earnings growth and favorable foreign exchange effects. Financial debt was unchanged, and other liabilities fell after a change in the discount rate applied to pension provisions. To wrap up my remarks, I want to call out a few cash flow developments that matter especially to me, since leverage growth also has to show up in stronger cash generation as the second level of value creation. Solid growth and working capital that stayed stable sequentially produced high single-digit growth in operating cash flow, bringing down net debt and the leverage ratio, as Kai mentioned earlier. Operating cash flow increased by almost 10% to EUR 1.66 billion in Q3, versus EUR 1.5 billion a year earlier in the same quarter. Starting from the table on slide 14, reported profit after tax fell mainly because of the impairment of the CDMO assets held for sale, which also caused the significant rise in D&A. Inside net working capital, lower trade payables weighed on cash flow, while receivables management and inventory levels moved in a favorable direction. Underlying cash generation has picked up markedly over recent months. Keeping that momentum going will stay a priority as we move to deleverage quickly after the planned Bio-Techne acquisition. As you may recall, in June we projected that the leverage ratio post-closing should sit below 3x net debt to EBITDA pre; it now looks possible that we will finish the year clearly under that level. Cash used in investing activity declined, which reflects disciplined spending and the completion of several larger investment projects. The main factor, though, was the liquidation of financial investments ahead of the expected closing of the Bio-Techne acquisition. Financing cash flow reflected repayment of a hybrid bond; with that, I will hand back to Kai.
Kai Beckmann
executiveThanks, Helene. I'm glad to be here to present, for a third time, an improved outlook for the full year 2026. I'll walk you through the specifics on slides 16 and 17. Group net sales organic growth is now projected at 3%-4%, up from the earlier 1%-3%. Currency headwinds eased during Q2 and have turned into a tailwind by Q3. The FX effect is now anticipated at -1%-0%, compared with -2%-0% before. As a result, group net sales should come in at roughly EUR 21.5 billion-EUR 21.9 billion, against our prior guidance of EUR 21 billion-EUR 21.8 billion. Beyond gains in fundamental operating results and stronger currency tailwinds, our December figures now incorporate an added portfolio effect stemming from Bio-Techne's contribution. Group EBITDA pre is now guided to EUR 6.2 billion-EUR 6.4 billion, up from the earlier EUR 5.9 billion-EUR 6.3 billion. That implies organic growth of 3%-5%, versus 0% to +3% previously. EPS pre should land between EUR 8.30-EUR 8.70, marking a 3% rise over the prior EUR 7.90 to EUR 8.60 range. Turning to business sector guidance, we have lifted the bottom end of our Life Science sales growth outlook yet again. For organic sales growth, we now anticipate a range of 6% to 7%, up from the 5% to 7% we gave in August. In absolute terms, the midpoint of our guidance rises to EUR 9.5 billion. This forecast also assumes that the Bio-Techne acquisition will be part of the portfolio for the Life Science business sector starting in December — that's an assumption on our part. The transaction's actual closing date could be different. On that basis, the portfolio effect would deliver a high double-digit million contribution for Life Science in 2026. For EBITDA pre-organic growth in Life Science, we now expect 6%-8%, compared with 5%-8% before. In absolute terms, the range's midpoint rises from EUR 2.7 billion to EUR 2.8 billion. Within Healthcare, we are now forecasting organic net sales development of -3% to -2%, versus -4% to -2% back in August; that shift reflects our Mavenclad U.S. assumptions, under which we now assume zero sales as of November — sorry — along with somewhat stronger performance elsewhere in the business. Healthcare EBITDA pre is anticipated at roughly EUR 2.9 billion to EUR 3 billion, up from the earlier EUR 2.8 billion to EUR 3 billion. For Electronics, we are once more lifting our organic net sales growth guidance, this time to 10%-11% from the prior 6% to 9%. For Electronics, we now anticipate EBITDA pre of roughly EUR 1.1 billion, up from the EUR 1 billion figure given in August. The corresponding range for organic EBITDA pre-growth shifts from 25%–29% to 33%–35%, which mirrors the operating leverage within Semiconductor Solutions as well as a comparable basis that one-off effects had impacted. To sum up, we made meaningful strategic and operational progress across 2026, and the guidance raise we announced today provides further evidence of that; having said this, I will hand things back to Florian.
Florian Schraeder
executiveThanks, Kai. Before we take questions on the lines, one last thing to share. We'd love for you to join our ESG investor update call, happening December 8 at 10:00 A.M. CET. During this 90-minute virtual session, investors and analysts focused on sustainability will get the chance to hear from our top management about what our ESG priorities are and the way those priorities support creating value over the long term. With that, I'll turn it over to Magdalena to start the Q&A.
Richard Vosser
analystHello, and thank you for taking my questions. I have two, please. My first is about Process Solutions. Could you perhaps share a bit more detail on what you're hearing from customers, which has also shaped what's showing up in the order book, and what has driven how you see Q4 unfolding, and maybe also give us some flavor on how you're thinking about next year for Process Solutions as well. My second question is about Pergoveris in the U.S.; we've seen some possible news today regarding the FDA perhaps dropping the CNPV process and winding it down. Maybe you could update us on where that review stands, and how we should view this as a possible opportunity for sales growth in 2027 for the Healthcare side of the business. Thanks so much.
Jean-Charles Wirth
executiveThank you, Richard. This is Jean-Charles speaking. I hope you're doing well. Let me take the first question regarding Process Solution, but perhaps before I get into process, I'd like to zoom out and give you a sense of our Q3 performance for total Life Science. Q3 was a solid quarter for Life Science with, as mentioned, organic growth of 6.1%. Excluding the tariff refund to customer, underlying growth would have come in at 7.3%. It's important to mention that we have a clean quarter with no special effects, apart from only this item around the tariff refund to customer. When you peel the onion, very solid performance in Advanced Solutions, 4.3% organically. Discovery Solutions, I would say, 1.7% organic growth, and we are pleased. Now let me zoom into your question on Process Solution. Process Solution delivered 10.5% organic growth year-over-year in Q3, and adjusted again for the effect related to the tariff refund, growth would have been 12.6%. We're seeing positive momentum across Process Solution, namely in downstream, in upstream, and single use. Every franchise posted positive organic growth this quarter. When you look at year-to-date September, I would say Process Solution is adding very strong sales growth. Speaking of year-to-date performance, I'd also like to mention that the book-to-bill ratio of Process Solution year-to-date September is above one. Now, regarding Q4 for Process Solution, we expect organic growth around mid-single digits due to a phasing effect. I want to repeat, due to a phasing effect. To be clear, it isn't about the underlying market. What does that mean for the full year? Number one, we're aiming to have a book-to-bill ratio for Process Solutions above one, and I'm very confident that PS growth will land in the upper end of our 8%-12% range for 2026 full year. In summary, I'd say everything is in order in Process Solutions. As to your question on 2027, you should understand that we won't provide guidance. The one thing we should all agree on is our comps. The comparisons for the first half of 2027 are going to be significantly tougher, while the second half should present an easier comparison. So stepping back and considering the midterm guidance that begins in 2026, we are confident in reaffirming our midterm outlook for Process Solution in 2027, which calls for organic growth in the 8% to 12% range.
Danny Bar-Zohar
executiveHi, Richard. Danny here. On Pergoveris, in that same spirit, let's step back a bit and look at the geographic rollout of Pergoveris; we launched it in China in March in the private market, and we're working toward NRDL inclusion. So far, we've seen fairly encouraging signs in China. But on your question about the U.S., in short, nothing has materially changed since what I said and the tone I used on the last call. We remain under review; we're working with the FDA, and we expect a decision in the coming months. You commented about the CNPV. Of course, we hold that CNPV. It hasn't expired. We filed. The file was accepted; but formally, on paper, it can take additional months for the FDA to complete its review, and of course we'll update you if we learn anything material. Meanwhile, we're preparing for a potential launch, as we already said on previous calls.
Richard Vosser
analystThanks a lot.
Peter Verdult
analystYeah, thank you. This is Peter Verdult from BNP Paribas. I have two questions. First, for Ben, could you help us roughly quantify the volume, price and mix that sit behind the 19% growth in Semiconductor Solutions you saw in Q3? We are pharma analysts rather than electronics specialists, so just remind us how much visibility you have across semi materials as we head into next year. What I am trying to work out is whether 2027 might be a year in which you trend above your midterm target of 7%-11% for Semiconductor Solutions. Then, more briefly and more broadly for Kai or Helene, the market is pricing in organic growth of roughly 4%-5% for next year. I fully understand this is not a guidance call for next year, but I do want to probe this with you and get a sense of your confidence that this is a plausible scenario, given that you have had some one-offs this year that will not recur next year, while you also appear to have very strong underlying momentum across Life Science and Electronics. Thank you.
Benjamin Hein
executiveThanks very much, Peter. This is Ben speaking. Let me take your first two questions on Electronics, one on price and volume and the second on the 2027 outlook. To give you some context, stepping back: as Kai and Helene mentioned, we lifted our organic sales growth guidance for Electronics from 6%-9% to 10%-11%. What is behind that? It is mostly advanced node ramps across Semiconductor Solutions, which have come in ahead of what we expected, but, to your question, we are also seeing a temporary pricing contribution. The majority, however, is driven by volume. We are actively managing our supply chain to support our customers and to ensure fair compensation for the contributions we are making. Again, against that strong demand backdrop, certain raw materials are tight in supply, and their market prices have risen significantly. For the full year 2026, we expect this pricing effect to add roughly 2 percentage points to organic sales growth in Semiconductor Solutions. To go a bit deeper, we expect roughly one-third in Q3 and two-thirds of that to occur in Q4. Looking ahead from a pricing standpoint, in our base case we expect raw materials market conditions to normalize over the course of 2027, with the associated pricing support from this particular effect fading accordingly. On the 2027 outlook for the industry overall, what we are seeing and hearing from our customers, particularly at the most advanced nodes and at the leading edge, is that capacity remains constrained and capacity remains very tight. The main driver of our growth continues to be advanced node ramps in logic, in memory, as well as in advanced packaging, which, as I said, have progressed ahead of our expectations. Our customers will be in Taiwan, Japan next week. They're putting in relentless effort to get more capacity up and running and to clear the supply bottlenecks; that's where the focus sits right now, and that's the outlook going into 2027. Still, I should say, as Kai mentioned, the consumer electronics application segment is still very much held down by high memory pricing and by the industry's focus on the AI segment specifically.
Kai Beckmann
executivePeter, thank you for that question. You're completely right that we aren't providing guidance today. It's still a very good question. Look, you heard me discuss solid underlying trends back in August, and in that respect, nothing has really changed. Market fundamentals remain fully intact. To look into next year, we first need to look into 2026, and we've raised our organic sales growth guidance for the third time in a row this year. That clearly highlights the strength of our portfolio. Naturally, as a base effect, this affects next year's growth outlook, perhaps slightly. Our teams have done a tremendous job managing the Mavenclad decline and making sure supply was available in H1, when demand in Process Solutions got an extra boost. Let me say it again: we have tough comps in PS in H1, and with Mavenclad U.S. sales falling almost 50% sequentially in Q3, it's only reasonable to expect a fairly steep Mavenclad decline in 2027. Returning to the upgraded group guidance for 2026, you'll notice a bit of an organic slowdown implied for Q4, and we expect that to carry into early next year. Let me step back. We feel fully confident in our midterm guidance. As I've laid out, there are a few effects you should factor in when considering organic growth in 2027. At the same time, we anticipate a significant boost to reported numbers for LS and the group from the recent sharpening of the portfolio and Bio-Techne in particular. Obviously, you'll hear more from us in March 2027; we'll share our quantitative guidance, and let's turn to Helene. Can you add anything?
Helene von Roeder
executiveYes, I can do that. I won’t go over all the points you just raised again, but there is one area I’d like to address regarding margins. Mavenclad will put pressure on Healthcare, and the R&D ratio could edge up somewhat because of items such as Silence Therapeutics. Even so, as I’ve mentioned a number of times, we are fully committed to keeping healthcare EBITDA pre-margin above 30%. When it comes to Life Science and Electronics, we have strong confidence in our ability to generate margin expansion. Both may reach 30% as early as next year. With that said, let me add a little more on Bio-Techne in this connection. Bio-Techne by itself will contribute nearly 5% to group sales and roughly 10% to Life Science. Although we stay fully committed to EPS pre-accretion in year three after closing, bear in mind that both Bio-Techne and the announced divestiture of the U.S. CDMO business will be immediately accretive to group and Life Science EBITDA pre-margin post-closing.
Peter Verdult
analystThanks.
Matthew Weston
analystAppreciate you taking our questions. We have two, please. I believe both are likely directed at Helene. Helene, at Vera Therapeutics, your partner, you've previously stated clearly that royalties get shared with Bristol and ZYMO; we had anticipated an approval milestone during 3Q, yet it appears to have been folded into the pharma or healthcare other income line. Can you verify that some portion of milestones is likewise passed along to Bristol and ZYMO? And if that's the case, could you provide a sensible proportion for future modeling that Merck will retain? The second one is just on Bio-Techne. You've discussed pushes and pulls, and you managed to move the transaction's closing ahead of schedule. As I remember, you hold an option to also accelerate full consolidation of Wilson Wolf, and that was something that was going to deliver additional accretion to the Bio-Techne deal. Might there be a chance that this too could arrive early and lift accretion in 2027?
Helene von Roeder
executiveMy colleagues are chomping at the bit to respond to your question, so I'll pass things first to Danny.
Danny Bar-Zohar
executiveThank you. Richard, regarding Vera, and regarding milestones and royalties, it's reasonable to assume Merck carries a meaningful obligation to BMS. Vera disclosed what they described, and I'm quoting them here, as a "low to mid-teens percent royalty rate." Still, in practically every scenario, our net royalty rate upside would stay within the single-digit percent range. Sorry, that was Matthew.
Matthew Weston
analystRegarding those milestones, Danny, does the same hold true there as well?
Danny Bar-Zohar
executiveI'm checking on that; once we've answered the second question, we'll follow up with you.
Helene von Roeder
executiveAll right, I can-
Matthew Weston
analystGreat
Helene von Roeder
executivelet's take the Wilson Wolf one. That's Q1 2028, and this closing cannot be moved.
Matthew Weston
analystAll right, thanks.
Danny Bar-Zohar
executiveSo Matthew, when it comes to the milestones, the proportions are much the same as what I mentioned earlier.
Matthew Weston
analystAll right, that's great. Thanks so much, the two of you.
James Quigley
analystThanks for having us ask our questions. There are two I'd like to raise, please — one about Life Science and one about Healthcare. On Life Science, a competitor of yours recorded higher growth in its lab division that was driven, at least in part, by AI. They also call out the bioanalytics instrument portfolio in that context. On your slides you mentioned that high-tech instruments have been recovering, largely thanks to pharma and biotechs. So what are you observing regarding a possible impact on Discovery Solutions and Advanced Solutions from whatever might be put down to greater activity stemming from AI? The second one is for Danny, about Gomekli and OGSIVEO. Sequential growth for each has decelerated this quarter. Is seasonality playing any role there, or is there something worth flagging that might help explain the quarter-on-quarter slowdown? How are the patient identification efforts going for the two drugs, what are you seeing on patient starts, and when might we begin to see an inflection in sales there? Thank you.
Jean-Charles Wirth
executiveHello, James. This is Jean-Charles. I'll take the first question, on the labs business and AI. From what we observe at customer level, there are no meaningful spending shifts as yet. It's fair to say the market has seen a large number of deal announcements involving biobugs, and over the mid to long term AI may lift demand for experimental validation. That being said, AI and innovation sit at the heart of our Merck Life Science strategy. As a concrete illustration, in executing that strategy we are working on AI solutions. Let me use this chance to give you a specific example. The first concerns Advanced Solutions. We introduced ChemisTwin, an AI-powered digital reference materials platform for analytical control, and it enables more sustainable testing for customers. The second example relates to drug Discovery Solutions. Both touch the lab business, and I'm referring to SYNTHIA Agentic AI, which is likewise an AI-powered digital chemistry solution that helps our customers design a target molecule successfully and, in fact, accelerates their research process overall. In short, to answer your question, we don't yet see significant spending shifts in the market. From a strategic standpoint, though, we are working hard on this, and I simply wanted to share those two concrete examples with you.
Danny Bar-Zohar
executiveHello, James. This is Danny. I appreciate your questions about OGSIVEO and Gomekli. We'll begin with OGSIVEO to provide a bit more detail on it. Q3 sales rose 24% year-over-year; quarter-over-quarter, the increase is 4%, and that comes from stronger U.S. demand, launches in additional countries, and greater named patient sales demand; now, I take encouragement from improving underlying demand metrics, which include growth in new patient starts, high refill rates, and discontinuations that are low and even trending slightly downward. That gives us confidence about growth in the quarters ahead. Can we do more? Yes, the answer is yes. We firmly believe we can, particularly in the U.S., or really for both OGSIVEO and Gomekli. Beyond those metrics, physician adoption remains very strong when you examine it. Among all treatment options, OGSIVEO continues to lead in satisfaction. Nearly every aware oncologist has prescribed it during the last 12 months. About 80% of oncologists expect their OGSIVEO usage to rise over the next year. More than 90% now regard the systemic therapy as the guideline-recommended first-line approach for progressing desmoid tumors. These leading indicators genuinely strengthen my confidence, and our confidence, in continued demand growth and the long-term opportunity for OGSIVEO. That is encouraging. Even so, a gap exists, as always in medicine, between awareness of, say, avoiding surgery and actually avoiding it; particularly with a chronic non-lethal disease, this takes time; we also anticipate commercial execution will strengthen in the fourth quarter and beyond, since we now benefit from a fully deployed field organization plus some recent investments aimed at further improving patient identification, treatment initiation, and persistence; additionally, new data generation studies are underway in key geographies to supply important answers, and this will also help enhance treatment for desmoid tumor patients. One more important point I want to mention relates to both products. We are picking up very nicely outside the U.S., and in fact, over the next year, we will launch in about 15, that is 1 to 5, countries; and experience in certain countries in Europe, and also beyond Europe, such as Saudi, such as Emirates, has been extremely positive. And I suppose you know that in rare diseases, one should not always expect two-thirds or more of revenue to come from the U.S. Now, a few words on Gomekli. There are some similarities with the market situation for Exxivio, but do not treat it as one-to-one. For Gomekli, Q3 rose 80% year-over-year, driven mainly by continued demand, again, in the U.S., along with patient uptake in Germany as well and named patient sales, which is encouraging. Sequential growth in Q3 is supported by very solid underlying patient dynamics. New patient starts climbed more than 20% versus the previous quarter, with September actually being one of the strongest months since launch. We are also encouraged by patient persistence, which reflects both how well the product is tolerated — something we knew would be strong — and our ongoing patient support initiatives, where we are very strong. Now, turning to competitive dynamics. As you know, with Gomekli we already face competition that has been on the market for over five years. I am actually quite pleased with where we stand in both the adult and pediatric segments. Adults now account for roughly 70% of our treatment volume. We were the first approved treatment for adult NF1-PN in the U.S., and Gomekli has established itself — clearly established itself — as the leading brand for new adult patient starts. We also keep building adoption in peds, backed by what I would call our differentiated clinical profile, tolerability, and convenience. The same potential for expansion and the same continued efforts will bring us, I would say, to the promised land, although both products will take more time to get there.
James Quigley
analystGreat, thanks.
Simon Baker
analystMany thanks for taking my questions. I have two, if I can, please. First, regarding the Life Science guidance raise. Since the range narrowed and the bottom end went up rather than the top, because of Bio-Techne being included, I was just wondering whether there were any other pushes and pulls besides Bio-Techne in there, or whether it is just a narrowing of the range given that we are three quarters through the year. Second, a question for Danny about Silence Therapeutics. Obviously, divesiran drove the deal, but I was just wondering whether you could speak to the opportunities you see beyond divesiran. There are a few other things in the portfolio, and in particular zerlasiran given the pelacarsen HORIZON data. Thanks so much.
Jean-Charles Wirth
executiveI'll take the first one, and it will be a brief answer. Bio-Techne will be treated as a portfolio effect. Bio-Techne will have no impact on our organic growth.
Danny Bar-Zohar
executiveOn Silence, absolutely, we’re really enthusiastic about divesiran. The phase II data are very strong and, in fact, check a lot of the boxes we described to you over the prior months. Homogeneous populations, rare diseases, phase II endpoints that lower risk for phase III; so we’re very excited about what it could become. As for your question on the Lp(a), you saw the recent presentation of the Novartis drug. It’s really disappointing. The drug clearly does what it’s meant to do pharmacodynamically, but clinically, not much, I’d say. From where we sit, the Lp(a) project isn’t one we’ll keep pursuing.
Simon Baker
analystOkay, thank you very much.
Thibault Boutherin
analystYes, many thanks. I have a question regarding Electronics. Could you give us some specifics on how Delivery Systems & Services performed in the quarter? Was its contribution meaningful? Has the trend changed at all? What visibility do you have for Q4, and how should we think about it looking toward 2027? Also, please clarify the PS phasing you mentioned, and the Q4 growth figure of mid-single digit. Can you confirm this phasing means nine strong months this year, with positive phasing across the first nine months turning to negative phasing in Q4? Does that phasing continue into next year? Thank you.
Benjamin Hein
executiveHi Thibault, thanks so much for that question. Ben here. Really appreciate you. Regarding DS&S, I can share some specifics. Delivery Systems & Services is expanding in general, yet during Q3 it pulled down Electronics growth. Just to remind everyone, DS&S accounts for less than 15% of the Electronics business as a whole. Since its base is comparatively small, the timing of major projects — which, again, we are carrying out at this moment — can shift it fairly easily from quarter to quarter. Big projects were once more the primary factor this quarter. We only take on new projects very selectively when they make economic sense for us, which is why we don't fold them into our base. What's encouraging, however, is that equipment has been improving. As you may recall, in the prior quarter we made a commitment that DS&S would be stabilizing, and in fact the equipment portion has been bouncing back rather well from the trough at the close of last year, which over time ought to leave DS&S as a whole relying less on the large project business. Semiconductor materials remains the primary growth engine for Semiconductor Solutions, and it is in turn driven by AI as well as the advanced nodes. For semiconductor materials we have now recorded an 11th straight quarter of year-over-year growth, averaging in the low teens.
Jean-Charles Wirth
executiveHello, Thibault. This is Jean-Charles. Allow me to clear things up and respond to what you asked regarding Process Solutions. What we are really discussing, above all, is phasing effects that move from Q3 into Q4. So what does that mean? It means that, when you consider the full year, our confidence is high. My own confidence is strong that Process Solutions will perform within the upper part of the guidance bridge we gave of between 8% and 12%. In addition, I want to restate something I mentioned earlier. One good indicator is our book-to-bill ratio, and we are moving toward having a book-to-bill ratio above one for the full year 2026. If you think about Process Solutions in 2026, I would say our outlook is one we are confident in, and we are moving toward a very strong performance this year.
Charles Pitman-King
analystHi, guys. This is Charles Pitman-King at Barclays. Many thanks for taking my questions. I have two, please. First, on EPS going into next year, given the higher tax guidance, the guided biotech dilution in EPS, and the effect of the Silence Therapeutics versus Lonza CDMO sale on net financials, plus Mavenclad's erosion starting in Q3 next year. I'm just wondering whether you can confirm that margin expansion from Life Science and Electronics will let you grow EPS next year. Second, on Process Solutions, regarding the order book, could you remind us of the typical lead time for your assets, since Merck is mainly exposed to the consumable side of the life science market, which should mean a shorter lead time, and what does that imply for the strength and visibility you have on how durable this order trend is? Essentially, this expectation of a declining order trend in FY 2027, how certain are you of it?
Helene von Roeder
executiveHey; so again, without giving guidance it is a bit hard to talk about EPS, but I can offer a bit of push and pulls if that helps. Number one, as you have seen, we have hedged Bio-Techne on the interest rate. That will be an important input factor. Number two, we were very clear on Healthcare that we will retain above the 30% margin. As I said earlier, we are also feeling pretty confident that we will be able to have that 30% margin in Life Science and Electronics. I think with that, you get most of the parameters to put the model together, and more to come next earnings call.
Jean-Charles Wirth
executiveHi Charles. This is Jean-Charles. Regarding your second question about PS lead time and visibility, I’ve said a number of times that by learning from the past, we’ve managed to rebuild our business trend history by region, by customer, by product order type, and back to 2018. We have roughly eight years of history, and I’d say we’ve been back to normal lead time now for a few quarters, and the average lead time is in the range of, let’s call it, one to six months for Process Solutions.
Florian Schraeder
executiveMaddalena, we have time for one last question.
Oliver Metzger
analystYes. Good afternoon, and thank you very much for fitting me in. My first question concerns Discovery Solutions. We're seeing what I'd call a fairly muted development there for a while now. You referenced biology in your slides as a growth driver, and also academia stabilizing. I'm certain you won't provide guidance for next year, but it would be wonderful to hear some of your thinking regarding a normalization across the coming quarters. My second question follows up on OGSIVEO and Gomekli, since you already hinted, "Okay, it doesn't make sense that the U.S. represents two-thirds." Could you remind us of the patient potential for a market outside the U.S. compared with the U.S.? Thank you.
Jean-Charles Wirth
executiveI'll begin with Discovery Solutions. At a very high level, within our Discovery Solution we have two franchises, biology and chemistry; we're also taking advantage of our multi-channel approach, which means drawing on our dealers, our beautiful e-commerce platform, our sales specialists, and our sales generalists. Overall, given the current market dynamic, it's true that we're seeing stabilization around academia; we're also seeing a kind of normalization across customer segments and regions. In a nutshell, when thinking about Discovery Solution, we should assume low single digits organic growth for this business. Again, I'm referring to low single digits without factoring in the Bio-Techne acquisition.
Danny Bar-Zohar
executiveAppreciate that, JC. Oliver here. Turning to the market opportunity, or how many patients OGSIVEO and Gomekli could reach outside the U.S.: when we announced the deal, we framed it around desmoid tumor, citing a potential of roughly 20,000 patients. That said, as I mentioned a few minutes back, developing that market and shifting referral patterns and physician behavior doesn't happen overnight—the potential exists, though the timeline to realize it may vary. A comparable scale of numbers applies to NF1-PN as well, across adult and pediatric populations—adults plus pediatric in Europe too. You can think in similar figures. Let me put it this way: for adults, both within the U.S. and beyond it, the upside is larger, since a lot of these untreated adults typically don't go to centers of excellence the way children do. But there's another point I want to make. At the time we announced the deal, we stated plainly that global expansion for both products is one of the main value drivers. As I mentioned a few minutes ago, you should anticipate that the ex-U.S. contribution will be quite substantial. That's where our strength lies — not only in Europe, not only in China. China will be part of it, Japan too, and emerging growth markets as well. I brought up the Middle East. There will be more. Thus, across each brand, there will be just 15 launches over the coming year—that's a substantial number, and it's exactly what you ought to keep in mind regarding the potential.
Oliver Metzger
analystThat is helpful. Thank you.
Operator
operatorThanks. Everyone, we appreciate you joining us. That brings this call to a close. You're free to disconnect now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.